ASH: Incyte, Novartis eye Jakafi approval with chronic graft vs. host win
Incyte and Novartis’ Jakafi already boasts an indication in acute graft vs. host disease (GVHD), thanks to an approval from last year. But it’s also eying a nod in the chronic form of the disease—and it may just have the data to get it done.
In a randomized phase 3 study—the first ever in chronic GVHD to come up successful—Jakafi was triggering a response in 49.7% of patients at 24 weeks, significantly topping the 25.6%-mark that a group of so-called best available therapies posted.
All of the patients had already failed on steroids, considered the “mainstay of treatment” in both acute and chronic GVHD, Peter Langmuir, Incyte’s VP of oncology drug development, said. They’d either responded “a bit” but seen their condition continue to worsen, or they hadn’t responded to steroid treatment at all.
The study, called Reach3 and presented over the weekend at the American Society of Hematology virtual annual meeting, also hit a few key secondary endpoints. 76.4% of Jakafi patients responded to treatment at some point throughout the 24-week period, versus 60.4% of patients on investigators’ choice of treatment.
The drug also significantly improved failure-free survival—defined as the amount of time until disease recurred, the patient started a new systemic treatment, or the patient died—and spurred patient-reported symptom improvements, too.
The win is a big one for Novartis and Incyte, considering how few advances the chronic GVHD field has seen in recent years. Less than 20% of chronic patients see lasting benefits a year after initial steroid therapy, John Tsai, M.D., Novartis’ chief medical officer, said.
Historically, many agents have had “anecdotal reports that look promising, but when you end up doing properly controlled trials, things don’t work out that well,” Incyte’s Langmuir added.
Next up for the partners? Getting the data to regulators as soon as possible. If they can eventually score a green light, it’ll follow up on last May’s FDA go-ahead in acute GVHD—a “different disease related to the same basic pathogenesis,” Langmuir said.
While both conditions arise after stem cell transplants and involve donor T cells reacting against the host body, chronic GVHD tends to develop more slowly than acute GVHD “can lead to a lifetime of complications,” Langmuir said. Those complications can be fatal, but in many cases, they just “lead to substantial morbidity for patients,” whose lungs, gastrointestinal systems, muscles and joints and mucus membranes may be affected.
And chronic GVHD has the potential to be a bigger indication for Jakafi, a blockbuster and the pioneering member of the JAK inhibitor class. There are about 1,500 new steroid-refractory cases in the U.S. each year, Langmuir said, but Incyte believes there are about 14,000 patients in the country right now suffering from the condition.
Acute disease also “tends to be fairly limited” compared with chronic GVHD. “People don’t live with acute for very long,” Langmuir pointed out. “It either is fatal or gets better or becomes chronic.”
On the other hand, “people can live for years” with chronic GVHD, he said.